Mitochondrially encoded ATP synthase 6 pseudogene 16 (MTATP6P16)

MTATP6P16, also known as ALS2CR3 or mitochondrially encoded ATP synthase 6 pseudogene 16, refers to a pseudogene related to the MT-ATP6 gene. MT-ATP6 itself encodes a mitochondrial protein essential for ATP synthesis and is involved in diseases such as Leigh syndrome and NARP syndrome[1][2][3][4][5]. However, the MTATP6P16 designation specifically references a pseudogene version, meaning it is a non-coding, nonfunctional DNA sequence in the nuclear genome with sequence similarity to the functional MT-ATP6 gene. Pseudogenes do not produce functional proteins, are not considered therapeutic targets, and have no known roles in signaling, disease pathogenesis, or drug action. There is no evidence that MTATP6P16 has any recognized biological function, disease association, or relevance for patient selection, drug safety, or efficacy monitoring. The inclusion of "pseudogene" in the name, and the lack of any mention in reputable disease or target databases, indicate that this molecule is not a therapeutically actionable target and is not considered in drug discovery, biomarker research, or molecular medicine. If a functional ATP synthase subunit is desired as a target, only the canonical MT-ATP6 gene (mitochondrially encoded ATP synthase membrane subunit 6) should be used for structured pharmacological or biomedical purposes[1][2][3][4][5].

Other names

ALS2CR3MT-ATP6 pseudogene 16mitochondrially encoded ATP synthase 6 pseudogene 16MTATP6P16